Work

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival

Year: 2014

Type: article

Source: Blood

DOI: 10.1182/blood.v124.21.2469.2469

Authors: Paul G. Richardson, Nancy A. Kernan, Stephan A. Grupp, Paul L. Martin, Robert J. Soiffer, Richard Martin, Alison L. Hannah, Kathleen F. Villa

Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Memorial Sloan Kettering Cancer Center, Children's Hospital of Philadelphia, Duke Medical Center, EUSA Pharma (United Kingdom), Jazz Pharmaceuticals (United States)

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1894907763

FWCI:

Cites:

Cited by:

Related to: 10